精鼎医药在港成立Health Advances亚洲分公司拓展亚太市场业务

2019-07-23 佚名 美通社

2019年7月23日,精鼎医药近日宣布其旗下医疗战略咨询公司Health Advances(医疗进阶)在中国香港成立亚洲分公司,以拓展其在亚太地区的业务范围,进一步提升在这一地区优化药物开发和商业化方案的能力。作为全球创新疗法开发领导者,精鼎医药致力于提供从临床到商业化的全流程解决方案,加快创新疗法的开发和运用,提高全球健康水平。精鼎医药在亚太地区已有20多年的历史,此次Health Advanc

2019年7月23日,精鼎医药近日宣布其旗下医疗战略咨询公司Health Advances(医疗进阶)在中国香港成立亚洲分公司,以拓展其在亚太地区的业务范围,进一步提升在这一地区优化药物开发和商业化方案的能力。作为全球创新疗法开发领导者,精鼎医药致力于提供从临床到商业化的全流程解决方案,加快创新疗法的开发和运用,提高全球健康水平。


精鼎医药在亚太地区已有20多年的历史,此次Health Advances亚洲分公司的成立将充分借助精鼎医药在亚太市场积累的丰富经验,助力这一地区的本土企业和跨国企业在全球范围内拓展业务。Health Advances亚洲分公司将由Gary Cheng领导,他在医药、生物技术和医疗技术等领域拥有超过30年的从业经验,曾服务过诺华、BD (Becton, Dickinson and Company)、奇隆公司(Chiron Corporation)、美艾利尔(Alere)、安万特(赛诺菲收购)等企业。此外,Health Advances旧金山办公室合伙人Vivek Mittal也将调任至中国香港办公室,与Gary Cheng及其团队通力合作,最大化满足客户业务需求。
 
Health Advances 对监管限制,转诊模式以及对可能影响医疗产品或医疗服务市场采用率的经济因素拥有丰富的经验见解, 可为客户提供创新的观点和可行性建议,帮助他们更有信心地做出战略商业决策, 在全球范围内抓住医疗技术、产品和服务的市场机遇, 实现增长。Health Advances的战略咨询服务是Parexel Biotech的重要组成部分,这一部门主要帮助新兴企业制定最快、最有效的流程,实现药物开发目标。Health Advances亚洲分公司目前拥有160名来自全球不同地区的员工,为包括大中华区、日本、韩国、澳大利亚、印度和东南亚在内的地区的企业提供战略咨询支持。
 
Health Advances联合创始人兼董事总经理Paula Ness Speers表示:“亚太地区的医疗市场正在快速增长,但是,对于该地区的本土企业和有计划拓展亚太市场的跨国企业来说,如何有效利用这一趋势,还需要深思熟虑,制定战略性商业决策。长期以来,Health Advances一直在协助跨国企业开拓和评估亚太市场,帮助亚太地区的本土企业寻求海外扩张的机会。此次Health Advances在亚洲成立分公司,意味着我们将有一个本土化的全职咨询团队随时为这一地区的客户提供支持。未来,在Vivek和Gary的领导下,我们的亚洲团队将全力以赴,为医疗健康行业中各细分领域的客户,提供专业的咨询服务,帮助他们充分了解和利用目前在本地市场和国际市场上存在的机遇。”
 
精鼎医药目前在大中华区拥有8个办事处,共1700多名员工。在亚太地区,精鼎医药拥有8000多名员工。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950408, encodeId=9db5195040882, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Mon Mar 09 23:11:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687584, encodeId=29eb168e58455, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Mon Jul 29 10:11:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861329, encodeId=4c1718613291e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Sep 09 01:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409868, encodeId=2b9b140986849, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621808, encodeId=66f61621808cf, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950408, encodeId=9db5195040882, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Mon Mar 09 23:11:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687584, encodeId=29eb168e58455, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Mon Jul 29 10:11:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861329, encodeId=4c1718613291e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Sep 09 01:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409868, encodeId=2b9b140986849, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621808, encodeId=66f61621808cf, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950408, encodeId=9db5195040882, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Mon Mar 09 23:11:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687584, encodeId=29eb168e58455, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Mon Jul 29 10:11:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861329, encodeId=4c1718613291e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Sep 09 01:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409868, encodeId=2b9b140986849, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621808, encodeId=66f61621808cf, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2019-09-09 shizhenshan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950408, encodeId=9db5195040882, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Mon Mar 09 23:11:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687584, encodeId=29eb168e58455, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Mon Jul 29 10:11:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861329, encodeId=4c1718613291e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Sep 09 01:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409868, encodeId=2b9b140986849, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621808, encodeId=66f61621808cf, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
    2019-07-25 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1950408, encodeId=9db5195040882, content=<a href='/topic/show?id=c53ce6612b8' target=_blank style='color:#2F92EE;'>#精鼎医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76612, encryptionId=c53ce6612b8, topicName=精鼎医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Mon Mar 09 23:11:00 CST 2020, time=2020-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687584, encodeId=29eb168e58455, content=<a href='/topic/show?id=0ea224245e4' target=_blank style='color:#2F92EE;'>#亚太#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24245, encryptionId=0ea224245e4, topicName=亚太)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef428388125, createdName=ms2536978994064944, createdTime=Mon Jul 29 10:11:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861329, encodeId=4c1718613291e, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Sep 09 01:11:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409868, encodeId=2b9b140986849, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621808, encodeId=66f61621808cf, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Jul 25 06:11:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]

相关资讯

精鼎医药携手CLARINESS 提升中国临床试验患者招募能力及患者参与度

2019年6月25日,全球创新疗法开发领导者精鼎医药今日宣布与全球领先的患者招募公司CLARINESS建立战略伙伴关系,助力加速中国的临床试验患者招募,提升患者参与度。近年来,在利好政策的支持和鼓励下,中国的临床试验数量急剧上升。根据国家药品监督管理局药品审评中心药物临床试验登记与信息公示平台的数据显示,2018年登记(获得CTR号)的临床试验总数为2579,相比2017年大幅增加了885个临床试

临床研究革新势在必行:以数字化转型加速药物开发创新

药物开发创新是一个周期长、高投资、高风险的过程,药物开发通常需要10年到15年的时间,投入资金会达到5到10亿美元。这个过程对于药企来说都是一个巨大的挑战,同时也是沉重的负担。各个药企现在正在积极地探索利用新的创新手段,提高临床试验、临床开发的效率,以及提高新产品上市的概率,这是所有制药企业所面临的共同的挑战。作为全球领先的生物制药服务创新企业,精鼎医药致力于在中国和全球推动实施创新,其旗下的